Switch theme
Sign up to access all valuation multiples
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
2015
188
LTM Revenue $206M
LTM EBITDA $5.6M
$818M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Avadel Pharmaceuticals has a last 12-month revenue (LTM) of $206M and a last 12-month EBITDA of $5.6M.
In the most recent fiscal year, Avadel Pharmaceuticals achieved revenue of $169M and an EBITDA of -$35.6M.
Avadel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Avadel Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $206M | XXX | $169M | XXX | XXX | XXX |
| Gross Profit | $187M | XXX | $154M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $5.6M | XXX | -$35.6M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -21% | XXX | XXX | XXX |
| EBIT | -$14.5M | XXX | -$42.4M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$21.8M | XXX | -$48.8M | XXX | XXX | XXX |
| Net Margin | -11% | XXX | -29% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Avadel Pharmaceuticals's stock price is $9.
Avadel Pharmaceuticals has current market cap of $881M, and EV of $818M.
See Avadel Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $818M | $881M | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Avadel Pharmaceuticals has market cap of $881M and EV of $818M.
Avadel Pharmaceuticals's trades at 4.8x EV/Revenue multiple, and -23.0x EV/EBITDA.
Equity research analysts estimate Avadel Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avadel Pharmaceuticals has a P/E ratio of -40.4x.
See valuation multiples for Avadel Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $881M | XXX | $881M | XXX | XXX | XXX |
| EV (current) | $818M | XXX | $818M | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 146.3x | XXX | -23.0x | XXX | XXX | XXX |
| EV/EBIT | -56.4x | XXX | -19.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -40.4x | XXX | -18.0x | XXX | XXX | XXX |
| EV/FCF | -62.4x | XXX | -17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAvadel Pharmaceuticals's last 12 month revenue growth is 42%
Avadel Pharmaceuticals's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.0M for the same period.
Avadel Pharmaceuticals's rule of 40 is -491% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Avadel Pharmaceuticals's rule of X is 109% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Avadel Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -21% | XXX | XXX | XXX |
| EBITDA Growth | 1363% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -491% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 109% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 116% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avadel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Avadel Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Avadel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Avadel Pharmaceuticals founded? | Avadel Pharmaceuticals was founded in 2015. |
| Where is Avadel Pharmaceuticals headquartered? | Avadel Pharmaceuticals is headquartered in United States of America. |
| How many employees does Avadel Pharmaceuticals have? | As of today, Avadel Pharmaceuticals has 188 employees. |
| Who is the CEO of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's CEO is Mr. Gregory J. Divis. |
| Is Avadel Pharmaceuticals publicy listed? | Yes, Avadel Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Avadel Pharmaceuticals? | Avadel Pharmaceuticals trades under AVDL ticker. |
| When did Avadel Pharmaceuticals go public? | Avadel Pharmaceuticals went public in 1996. |
| Who are competitors of Avadel Pharmaceuticals? | Similar companies to Avadel Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's current market cap is $881M |
| What is the current revenue of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's last 12 months revenue is $206M. |
| What is the current revenue growth of Avadel Pharmaceuticals? | Avadel Pharmaceuticals revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Avadel Pharmaceuticals? | Current revenue multiple of Avadel Pharmaceuticals is 4.0x. |
| Is Avadel Pharmaceuticals profitable? | Yes, Avadel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's last 12 months EBITDA is $5.6M. |
| What is Avadel Pharmaceuticals's EBITDA margin? | Avadel Pharmaceuticals's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Avadel Pharmaceuticals? | Current EBITDA multiple of Avadel Pharmaceuticals is 146.3x. |
| What is the current FCF of Avadel Pharmaceuticals? | Avadel Pharmaceuticals's last 12 months FCF is -$13.1M. |
| What is Avadel Pharmaceuticals's FCF margin? | Avadel Pharmaceuticals's last 12 months FCF margin is -6%. |
| What is the current EV/FCF multiple of Avadel Pharmaceuticals? | Current FCF multiple of Avadel Pharmaceuticals is -62.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
